Earnings announcements by leading domestic pharmaceutical companies and pharmaceutical wholesalers will get into full swing from today. The impact of the fiscal 2026 drug price revision, patent expiry, new product trends, growth in overseas operations, and higher costs due to rising prices will be key areas of focus.
Earnings announcements by leading domestic pharmaceutical companies and pharmaceutical wholesalers will get into full swing. The performance outlook for the current fiscal year is attracting market attention.
Key areas of focus include the impact of the fiscal 2026 drug price revision, the impact of patent expiry for core products, and growth in new products and overseas operations. Attention will focus on how these factors are addressed in each company's announcement.
Higher costs across the board due to rising prices are also expected to be an important factor under consideration, and changes in sales structures and cost-management trends could affect companies' financial performance.